In studies to demonstrate the significance of c-Met inhibition, Yue et al.[48] reported that miR-182 directly targets the c-MET gene in BC cells and that miR-182 downregulation is associated with trastuzumab resistance in BC cells. Here, MET is linked to breast cancer.